Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02310464
Title Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors OBI Pharma, Inc

lung non-small cell carcinoma

colorectal cancer

stomach cancer

lung cancer

breast cancer


OBI-821 + OBI-833

Age Groups: adult | senior
Covered Countries

No variant requirements are available.